Therapeutic agent for migraine
US9254283B2 · kind B2 · utility
10Cited by
10References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2009 |
| Grant date | Feb 9, 2016 |
| Priority date | — |
| Expiry date | Jan 15, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof; therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A2A receptor antagonistic activity, which has an affinity for the adenosine A2A receptor 10 times or higher than that for the adenosine A1 receptor, or a pharmaceutically acceptable salt thereof; and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.